Phase 1, window of opportunity study of parasympathetic stimulation with bethanechol in localized pancreatic adenocarcinoma prior to surgery.

Protocol: 
AAAR6735
Phase: 
I

Phase 1, window of opportunity study of parasympathetic stimulation with bethanechol in localized pancreatic adenocarcinoma prior to surgery.

1. Are you 18 years of age or greater?
2. Do you have recurrent glioblastoma?
3. Is this the first or second time your glioblastoma reoccurred?
4. Did your first treatment include radiotherapy and temozolomide?

Are you Eligible? (Inclusion Criteria)

The purpose of this study is to determine whether the drug, bethanechol,
could potentially be used in combination with surgery to decrease the chance
of the cancer coming back after it is removed. Bethanechol is a medication
that regulates the parasympathetic nervous system and is often used to
manage the side effects of chemotherapy drugs and to manage urinary
retention. Studies of pancreatic cancer in animal models have shown that
treatment with bethanechol can inhibit cancer growth and spread. People with
pancreatic cancer localized to a small area usually undergo surgery to
remove the tumor.

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States